<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01032174</url>
  </required_header>
  <id_info>
    <org_study_id>A0661199</org_study_id>
    <nct_id>NCT01032174</nct_id>
  </id_info>
  <brief_title>Non-Interventional Open Label Prospective Comparative Observational Study Of Evaluation Of Compliance In The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Of Acute Bacterial Maxillary Sinusitis</brief_title>
  <acronym>EASY</acronym>
  <official_title>Non-Interventional Open Label Prospective Comparative Observational Study Of Evaluation Of Compliance In The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Of Acute Bacterial Maxillary Sinusitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare compliance between patients with Acute Bacterial
      Sinusitis (ABS) treated with Azithromycin SR 2.0 g single dose orally and those treated with
      Amoxiclav - 1000 mg twice daily 10 days for the empiric treatment of ABS in outpatient clinic
      practice.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Response of Very Convenient or Somewhat Convenient</measure>
    <time_frame>Day 11</time_frame>
    <description>Participant reported outcome questionnaire was the assessment of participant's convenience with drug treatment based on following categories: very convenient or somewhat convenient and not convenient or not at all convenient. Value of 1 was reported if participant answered 'very convenient' or 'somewhat convenient' and 0 if participant answered 'not convenient' or 'not at all convenient'.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Compliance With Prescribed Treatment Regimen</measure>
    <time_frame>Day 11</time_frame>
    <description>Percent compliance with the prescribed treatment regimen was calculated as 100 multiplied by (number of tablets taken by the participant divided by number of tablets prescribed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were 100 Percent Compliant With Prescribed Treatment Regimen</measure>
    <time_frame>Day 11</time_frame>
    <description>Percent compliance with the prescribed treatment regimen was calculated as 100 multiplied by (number of tablets taken by the participant divided by number of tablets prescribed). Value of 1 was reported if percent compliance equals to 100, and 0 if percent compliance was non-missing and less than 100.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">123</enrollment>
  <condition>Maxillary Sinusitis</condition>
  <arm_group>
    <arm_group_label>Azithromycin SR</arm_group_label>
    <description>Acute Bacterial Maxillary Sinusitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amoxiclav 1000 mg</arm_group_label>
    <description>Acute Bacterial Maxillary Sinusitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin SR</intervention_name>
    <description>Azithromycin SR, 2.0 g by mouth (PO) x 1</description>
    <arm_group_label>Azithromycin SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxiclav 1000 mg</intervention_name>
    <description>Amoxiclav 1000 mg x twice daily, 10 days</description>
    <arm_group_label>Amoxiclav 1000 mg</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Acute Maxillary Sinusitis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or nor pregnant or lactating female outpatients, 18 years of age or older.

          -  A clinical diagnosis of acute bacterial uncomplicated maxillary sinusitis as
             demonstrated by presence of the following signs and symptoms for a minimum duration of
             7-10 days:

               1. Facial pain, pressure and/or tightness over one or both maxillary sinuses, and/or
                  pain in one or both maxillary areas that worsens with movement or percussion, and

               2. Presence of one or more of the following signs:

             i.purulent nasal discharge ii.purulent drainage in the posterior pharynx iii.purulent
             discharge from the maxillary sinus orifice

          -  A sinus X-ray (Water's view) confirming the clinical diagnosis of maxillary sinusitis.
             At least one of the following must be documented in one or both maxillary sinuses on
             radiologic examination:

               1. complete or partial opacification

               2. an air/fluid level

        Two or more of the following:

          1. fever, as defined by temperature: &gt;38ÂºC

          2. leukocytosis [White Blood Cell (WBC) &gt;10,000/mm3 or &gt;15% band forms], ECR;

          3. headache,

          4. nasal congestion and post nasal drainage.

        Exclusion Criteria:

          -  Known or suspected hypersensitivity or intolerance or contraindications to
             Azithromycin, Amoxiclav according to LPDs, pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0661199&amp;StudyName=Non-Interventional%20Open%20Label%20Prospective%20Comparative%20Observational%20Study%20Of%20Evaluation%20Of%20Compliance%20In%20The%20Empiric%20Treatment%20With%20Azithromyc</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2009</study_first_submitted>
  <study_first_submitted_qc>December 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2009</study_first_posted>
  <results_first_submitted>February 21, 2012</results_first_submitted>
  <results_first_submitted_qc>February 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 22, 2012</results_first_posted>
  <last_update_submitted>April 10, 2012</last_update_submitted>
  <last_update_submitted_qc>April 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Azithromycin SR Amoxiclav 1000 mg Maxillary Sinusitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Maxillary Sinusitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Azithromycin</title>
          <description>A single dose of azithromycin 2000 milligram (mg) sustained release (SR) tablet administered orally.</description>
        </group>
        <group group_id="P2">
          <title>Amoxiclav</title>
          <description>Amoxiclav 1000 mg tablet administered twice daily (BID) orally for 10 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Azithromycin</title>
          <description>A single dose of azithromycin 2000 milligram (mg) sustained release (SR) tablet administered orally.</description>
        </group>
        <group group_id="B2">
          <title>Amoxiclav</title>
          <description>Amoxiclav 1000 mg tablet administered twice daily (BID) orally for 10 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="123"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.9" spread="11.6"/>
                    <measurement group_id="B2" value="38.4" spread="13.4"/>
                    <measurement group_id="B3" value="37.6" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Response of Very Convenient or Somewhat Convenient</title>
        <description>Participant reported outcome questionnaire was the assessment of participantâs convenience with drug treatment based on following categories: very convenient or somewhat convenient and not convenient or not at all convenient. Value of 1 was reported if participant answered âvery convenientâ or âsomewhat convenientâ and 0 if participant answered ânot convenientâ or ânot at all convenientâ.</description>
        <time_frame>Day 11</time_frame>
        <population>The Full Analysis Set (FAS) population included all participants who received at least 1 dose of study medication and had at least 1 post-baseline efficacy evaluation. 'N' signifies number of participants with non-missing data. Missing observations were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin</title>
            <description>A single dose of azithromycin 2000 milligram (mg) sustained release (SR) tablet administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Amoxiclav</title>
            <description>Amoxiclav 1000 mg tablet administered twice daily (BID) orally for 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response of Very Convenient or Somewhat Convenient</title>
          <description>Participant reported outcome questionnaire was the assessment of participantâs convenience with drug treatment based on following categories: very convenient or somewhat convenient and not convenient or not at all convenient. Value of 1 was reported if participant answered âvery convenientâ or âsomewhat convenientâ and 0 if participant answered ânot convenientâ or ânot at all convenientâ.</description>
          <population>The Full Analysis Set (FAS) population included all participants who received at least 1 dose of study medication and had at least 1 post-baseline efficacy evaluation. 'N' signifies number of participants with non-missing data. Missing observations were not imputed.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The logistic regression model contained terms for treatment, gender and age.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Compliance With Prescribed Treatment Regimen</title>
        <description>Percent compliance with the prescribed treatment regimen was calculated as 100 multiplied by (number of tablets taken by the participant divided by number of tablets prescribed).</description>
        <time_frame>Day 11</time_frame>
        <population>The FAS population included all participants who received at least 1 dose of study medication and had at least 1 post-baseline efficacy evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin</title>
            <description>A single dose of azithromycin 2000 milligram (mg) sustained release (SR) tablet administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Amoxiclav</title>
            <description>Amoxiclav 1000 mg tablet administered twice daily (BID) orally for 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Compliance With Prescribed Treatment Regimen</title>
          <description>Percent compliance with the prescribed treatment regimen was calculated as 100 multiplied by (number of tablets taken by the participant divided by number of tablets prescribed).</description>
          <population>The FAS population included all participants who received at least 1 dose of study medication and had at least 1 post-baseline efficacy evaluation.</population>
          <units>Percent compliance</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" spread="0.00"/>
                    <measurement group_id="O2" value="99.00" spread="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0568</p_value>
            <p_value_desc>The analysis of covariance (ANCOVA) model contained terms for treatment, gender, age and Body Mass Index (BMI).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Least square mean was adjusted for gender, age and BMI.</method_desc>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>1.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>2.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were 100 Percent Compliant With Prescribed Treatment Regimen</title>
        <description>Percent compliance with the prescribed treatment regimen was calculated as 100 multiplied by (number of tablets taken by the participant divided by number of tablets prescribed). Value of 1 was reported if percent compliance equals to 100, and 0 if percent compliance was non-missing and less than 100.</description>
        <time_frame>Day 11</time_frame>
        <population>The FAS population included all participants who received at least 1 dose of study medication and had at least 1 post-baseline efficacy evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin</title>
            <description>A single dose of azithromycin 2000 milligram (mg) sustained release (SR) tablet administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Amoxiclav</title>
            <description>Amoxiclav 1000 mg tablet administered twice daily (BID) orally for 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were 100 Percent Compliant With Prescribed Treatment Regimen</title>
          <description>Percent compliance with the prescribed treatment regimen was calculated as 100 multiplied by (number of tablets taken by the participant divided by number of tablets prescribed). Value of 1 was reported if percent compliance equals to 100, and 0 if percent compliance was non-missing and less than 100.</description>
          <population>The FAS population included all participants who received at least 1 dose of study medication and had at least 1 post-baseline efficacy evaluation.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0682</p_value>
            <p_value_desc>The logistic regression model contained terms for treatment, gender and age.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Azithromycin</title>
          <description>A single dose of azithromycin 2000 milligram (mg) sustained release (SR) tablet administered orally.</description>
        </group>
        <group group_id="E2">
          <title>Amoxiclav</title>
          <description>Amoxiclav 1000 mg tablet administered twice daily (BID) orally for 10 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

